604
Participants
Start Date
April 30, 2005
Primary Completion Date
January 31, 2007
Study Completion Date
October 31, 2011
LPV/rtv
One 400mg LPV tablet twice daily with 100mg RTV
TMC114/rtv
Two 300mg TMC114 tablets twice daily with 100mg RTV
Phoenix
Little Rock
Beverly Hills
Long Beach
Los Angeles
San Francisco
West Hollywood
Denver
Washington D.C.
Fort Lauderdale
Miami
Orlando
Safety Harbor
Tampa
Vero Beach
Atlanta
Macon
Chicago
Boston
Berkley
Camden
East Orange
Newark
The Bronx
Durham
Huntersville
Winston-Salem
Cleveland
Portland
Philadelphia
Columbia
Austin
Dallas
Galveston
Houston
Longview
Hampton
Seattle
Milwaukee
Buenos Aires
Córdoba
Rosario
Darlinghurst
Melbourne
Perth
Surry Hills
Vienna
Antwerp
Brussels
Curitiba
Distrito Barao Geraldo-Campina
Nova Iguaçu
Pinheiros
Rio de Janeiro
São Paulo
Calgary
Ottawa
Toronto
Montreal
Providencia
Santiago
Aalborg
Nice
Paris
Rennes
Villejuif
Aachen
Berlin
Cologne
Düsseldorf
Hamburg
Mannheim
Osnabrück
Stuttgart
Melissia-Athens
Guatemala City
Budapest
Kuala Lumpur
Sungai Buloh
Guadalajara
Amsterdam
Groningen
Rotterdam
Panama City
Lisbon
Porto
San Juan
Kazan'
Moscow
Nizhny Novgorod
Saint Petersburg
Volgograd
Cape Town
Durban
Houghton, Johannesburg
Johannesburg
Pretoria
Barcelona
Madrid
Zurich
Bangkok
Khon Kaen
London
Tibotec Pharmaceuticals, Ireland
INDUSTRY